ORC6 Antibody [E10G21]

N° de catalogue F6758

Imprimer

Description biologique

Spécificité ORC6 Antibody [E10G21] détecte les niveaux endogènes de la protéine ORC6 totale.
Contexte ORC6 (Origin Recognition Complex Subunit 6) est un composant essentiel du complexe de reconnaissance d'origine hétérohexamérique qui se lie aux origines de réplication en phase G1, recrutant Cdc6 et Cdt1 pour assembler les complexes pré-réplicatifs et licencier les origines chromosomiques pour un déclenchement précis en phase S, tout en stabilisant l'association de l'hélicase MCM2-7 avec la chromatine pour assurer une duplication complète du génome. ORC6 se localise aux fourches de réplication en tant que facteur accessoire dans la réparation des mésappariements, recrutant directement MutSα (MSH2-MSH6) et MutLα (MLH1-PMS2) pour faciliter la reconnaissance des lésions de l'ADN, l'activation de MutLα et la signalisation des dommages médiée par ATR, préservant ainsi l'intégrité génomique pendant le stress de réplication. Il présente une région de répétition hélicoïdale de type TFIIB N-terminale contenant des résidus de liaison à l'ADN Q129, R137 et K168, et un domaine de cytokinèse C-terminal qui interagit avec les septines au niveau du corps médian pour séparer physiquement les cellules filles et prévenir la binucléation. Les mutations dans ORC6 perturbent l'assemblage des pré-RC, provoquant le syndrome de Meier-Gorlin, un trouble caractérisé par de profonds défauts de développement, notamment une microcéphalie, un nanisme primordial et une hypoplasie de la rotule due à un échec de la licence de réplication. La surexpression d'ORC6 hyperactive les origines de réplication, entraînant une prolifération, une migration et une invasion incontrôlées avec un mauvais pronostic dans le cancer du poumon non à petites cellules, le carcinome hépatocellulaire, le carcinome à cellules rénales et le cancer du sein, ainsi que des rôles inflammatoires émergents médiés par NFκB dans la dysrégulation immunitaire.

Informations dutilisation

Application WB, IP Dilution
WB IP
1:1000 1:50
Réactivité Human, Mouse, Rat, Hamster, Monkey
Source Rat Monoclonal Antibody MW 28 kDa
Tampon de stockage PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
Stockage
(À partir de la date de réception)
-20°C (avoid freeze-thaw cycles), 2 years
WB
Experimental Protocol:
 
Sample preparation
1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/Nuclear Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature.
2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/Nuclear Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min.
3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/Nuclear Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min.
4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
5. Remove a small volume of lysate to determine the protein concentration;
6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
 
Electrophoretic separation
1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
 
Transfer membrane
1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
Recommended conditions for wet transfer: 200 mA, 60 min.
( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
 
Block
1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
2. Incubate the film in the blocking solution for 1 hour at room temperature;
3. Wash the film with TBST for 3 times, 5 minutes each time.
 
Antibody incubation
1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
2. Wash the film with TBST 3 times, 5 minutes each time;
3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
 
Antibody staining
1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.

Références

  • https://pubmed.ncbi.nlm.nih.gov/32986843/
  • https://pubmed.ncbi.nlm.nih.gov/19541634/

Données dapplication

WB

Validé par Selleck

  • F6758-wb
    Lane 1: Hela, Lane 2: HUVEC, Lane 3: NIH/3T3, Lane 4: C6